Clinical Trials Browser

INDUSTRY × tepotinib × Clear all

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase 2 Active not recruiting

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04739358 2023-10-18

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03492437 2023-08-07

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Phase 1 Completed

20 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Phase 2 Terminated

3 enrolled 6 charts

Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms

NCT01014936 2022-08-24

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Phase 1 Completed

149 enrolled 41 charts

Other solid neoplasm

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

NCT01988493 2022-08-24

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Phase 1/2 Completed

117 enrolled 30 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02115373 2022-08-24

c-Met Second-Line Hepatocellular Carcinoma

Phase 1/2 Completed

66 enrolled 34 charts

Gastrointestinal

Carcinoma, Hepatocellular